Shire's Vyvanse wins 1st 'binge-eating' indication
This article was originally published in Scrip
Executive Summary
Shire picked up another indication for Vyvanse (lisdexamfetamine dimesylate) – winning the first approval in the US for a drug to help curb episodes of binge-eating in adults with the disorder.